SS-31 (D-Arg-Dmt-Lys-Phe-NH2), also known by its clinical name Elamipretide, is a cell-permeable tetrapeptide that selectively targets the inner mitochondrial membrane. It binds to cardiolipin, a phospholipid essential for electron transport chain function, stabilizing mitochondrial cristae structure and improving oxidative phosphorylation efficiency. SS-31 is currently in advanced clinical trials for conditions involving mitochondrial dysfunction including primary mitochondrial myopathy (Barth syndrome), heart failure, and age-related macular degeneration. Research demonstrates that SS-31 can reverse age-related decline in mitochondrial function, making it a cornerstone compound in aging research. Available in high-purity lyophilized form for research applications.
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 |
| Molecular Formula | C32H49N9O5 |
| Molecular Weight | 639.79 g/mol |
| Purity | ≥95% (HPLC) |
| Form | Lyophilized powder |
| Storage | -20°C |
| CAS | 736992-21-5 |
Mitochondria-targeted tetrapeptide for cellular energy restoration and age-related mitochondrial dysfunction research.
We supply SS-31 (Elamipretide) at ≥95% (HPLC) purity. Higher purity grades are available for pharmaceutical applications upon request.
Minimum order quantities for wholesale SS-31 (Elamipretide) depend on the quantity and purity grade required. Contact our sales team for specific pricing and MOQ information.
SS-31 (Elamipretide) should be stored at -20°C in a desiccated environment. Proper cold-chain shipping is maintained for all deliveries.
Synthetic tetrapeptide that activates telomerase enzyme, studied for its potential anti-aging and lo...
View Details Research PeptidesSynthetic nootropic and anxiolytic heptapeptide developed for cognitive enhancement, anxiety reducti...
View Details Research PeptidesSynthetic nootropic heptapeptide derived from ACTH for cognitive enhancement, neuroprotection, and i...
View Details Research PeptidesNeuropeptide for sleep normalization, stress resilience enhancement, and circadian rhythm regulation...
View Details